Merus and Halozyme partner on subcutaneous petosemtamab formulation
Go back to Merus and Halozyme partner on subcutaneous petosemtamab formulation| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 107.62 +2.73 (2.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $104.89 | 52 Week High | $18.39 | |||
| Open | $106.39 | 52 Week Low | $6.96 | |||
| Day High | $107.96 | P/E | N/A | |||
| Day Low | $105.50 | EPS | $-0.58 | |||
| Volume | 2,539,526 | |||||
| (NASDAQ: MRUS) | Delayed: 90.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.00 | 52 Week High | $19.63 | |||
| Open | $90.00 | 52 Week Low | $7.26 | |||
| Day High | $90.00 | P/E | N/A | |||
| Day Low | $90.00 | EPS | $0.00 | |||
| Volume | 647,529 | |||||
